Ascendis Pharma A/S (ASND) Q3 2015 Earnings Results

Ascendis Pharma Misses on Revenue, Stock Down 6.73%

Ascendis Pharma reported a narrower-than-expected loss per share, beating EPS estimates significantly. However, the stock fell by 6.73%, indicating that investors may have been disappointed by the lack of revenue information and guidance. The absence of management commentary also leaves uncertainty about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.32	N/A	+43.68%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record, so the analysis is based solely on numerical results.

Ascendis Pharma Misses on Revenue, Stock Down 6.73%

Key numbers

Management commentary

Ascendis Pharma A/S

More earnings this week

Ascendis Pharma Misses on Revenue, Stock Down 6.73%

Key numbers

Management commentary